Last €8.78 EUR
Change Today +0.16 / 1.86%
Volume 1.4M
IPH On Other Exchanges
Symbol
Exchange
EN Paris
Frankfurt
OTC US
As of 11:35 AM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

innate pharma sa (IPH) Snapshot

Open
€8.90
Previous Close
€8.62
Day High
€9.22
Day Low
€8.67
52 Week High
02/12/14 - €12.30
52 Week Low
09/4/13 - €2.24
Market Cap
465.0M
Average Volume 10 Days
416.8K
EPS TTM
€-0.07
Shares Outstanding
53.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INNATE PHARMA SA (IPH)

Related News

No related news articles were found.

innate pharma sa (IPH) Related Businessweek News

No Related Businessweek News Found

innate pharma sa (IPH) Details

Innate Pharma S.A., a biopharmaceutical company, is engaged in the research and development of pharmaceutical products primarily immunotherapy drug candidates for cancer and inflammatory diseases in France. The company develops monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its product candidates in clinical development comprise Lirilumab (IPH2102/BMS-986015), a monoclonal antibody (IgG4) blocking killer-cell immunoglobulin-like receptors in Phase II clinical trials for cancer and two Phase I clinical trials to solid tumors in combination with ipilimumab and nivolumab; and IPH2201, an IgG4 antibody, which is in Phase I clinical trials for the treatment of rheumatoid arthritis. The company is also involved in the pre-clinical development of IPH4102, a cytotoxic mAb that targets KIR3DL2. In addition, it is engaged in IPH33 program, a monoclonal antibody program that targets Toll-like Receptor-3 receptor, which is an inducer of Type I IFN and pro-inflammatory cytokines; and IPH43 program for the development of anti-MICA therapeutic antibody in oncology. It has licensing agreements with Bristol-Myers Squibb and Novo Nordisk A/S. Innate Pharma S.A. was founded in 1999 and is headquartered in Marseilles, France.

84 Employees
Last Reported Date: 04/7/14
Founded in 1999

innate pharma sa (IPH) Top Compensated Officers

Co-Founder, Chairman of Executive Board and C...
Total Annual Compensation: €305.2K
Co-Founder and Member of Scientific Advisory ...
Total Annual Compensation: €214.0K
Executive Vice-President, Senior Advisor Fina...
Total Annual Compensation: €244.5K
Compensation as of Fiscal Year 2013.

innate pharma sa (IPH) Key Developments

Enzo Biochem Inc. Unit Partners with Innate Pharma S.A. to Validate Key System for Antibody Drug Conjugate Development

Enzo Biochem Inc. announced that its Life Sciences division has established a collaboration with Innate Pharma S.A. to support a novel application of its ProteoStat(R) products for antibody-drug conjugate (ADC) design. ADCs are monoclonal antibodies engineered to go unnoticed, delivering cytotoxic drugs to cells expressing the antigen target. Cancer therapy has become the most prevalent application area, with 30 ADCs currently in clinical trials. Successful development of an ADC requires optimization of several elements, including the antibody, the potency of the cytotoxic drug, the stability of the linker, the site of conjugation and the stoichiometry of the resulting adducts. Innate Pharma specializes in the development of new monoclonal antibodies targeting cancer and inflammatory diseases. Early on in the development process, Innate Pharma recognized the need for reliable methods to evaluate the stability of these ADC products in aqueous liquid form. Long-term stability was critical for validating the technology concept for clinical applications. As such, Innate Pharma looked to Enzo Life Sciences to provide assays for screening the stability and aggregation properties of their ADCs.

Innate Pharma S.A. Presents at Citi European Healthcare Conference, Jun-19-2014

Innate Pharma S.A. Presents at Citi European Healthcare Conference, Jun-19-2014 . Venue: Stirling Square, 5-7 Carlton Gardens, London SW1Y 5AD, United Kingdom. Speakers: Catherine Moukheibir, Senior Advisor of Finance and Member of Executive Board, Laure-Hélène Mercier, Director of Investor Relations.

Innate Pharma S.A. Presents at Jefferies 2014 Global Healthcare Conference, Jun-05-2014 02:30 PM

Innate Pharma S.A. Presents at Jefferies 2014 Global Healthcare Conference, Jun-05-2014 02:30 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Nicolai Wagtmann, Chief Scientific Officer, Executive Vice President and Member of Executive Board.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPH:FP €8.78 EUR +0.16

IPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IPH.
View Industry Companies
 

Industry Analysis

IPH

Industry Average

Valuation IPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.5x
Price/Book 9.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INNATE PHARMA SA, please visit www.innate-pharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.